

Emcure's European subsidiary Tillomed buys strategic pharma portfolio from Manx for £19.7 M

04 April 2025 | News

To strengthen the company's product offerings and expand its market reach



Tillomed Laboratories, a subsidiary of Pune-based Emcure Pharmaceuticals, and a leading European pharma company, has entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare and its subsidiaries Manx Pharma and Manx Generics.

Under the APA, Tillomed will acquire Manx's product portfolio inclusive of relevant Dossiers, Marketing Authorisations, Intellectual Property (collectively Intellectual Properties) and the relevant stocks for around £ 19.7 million (including £ 4.7 million for inventory) of which £ 6.2 million will be upfront and rest as milestone payments over the next 18 months.

The deal marks a strategic milestone for Tillomed and will strengthen the company's product offerings, expand its market reach, and enhance its ability to meet the evolving needs of patients.

Commenting on the development, Ajit Simal, CEO Tillomed said, "Through the acquisition of Manx's established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions. The acquired assets will help diversify our portfolio and strengthen our market presence."

Headquartered in Luton, UK, Tillomed operates across multiple European markets, ensuring access to cost-effective healthcare solutions. As an Emcure subsidiary, Tillomed leverages world-class research, manufacturing, and distribution expertise to bring innovative and affordable medicines to patients.